Sequencing of treatments for advanced kidney cancer remains uncertain

There are now a number of licensed drug options available for the treatment of advanced renal cell carcinoma (RCC). Many of them have data supporting their use as first- and second-line treatments. However, it is still not clear what sequence these drugs should be used in, especially as data coming out of clinical trials may […]

read more

Type of long-term response to targeted therapy affects outcomes for advanced kidney cancer

A retrospective study conducted by researchers in the Czech Republic has analysed the outcomes of 219 people with metastatic renal cell carcinoma (mRCC) who received first-line treatment with vascular endothelial growth factor (VEGF) inhibitors, for example sunitinib, sorafenib, pazopanib, or bevacizumab, for at least 2 years. The vast majority of patients (166 patients, 75.8%) received […]

read more

Novel treatment options for kidney cancer presented at ASCO 2017

The following video is an interview between PracticeUpdate and Dr Bradley Somer, Assistant Professor in the Department of Haematology/Oncology at the University of Tennessee Health Science Center at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago last week. During the interview, Dr Somer talks about the results from a recent clinical trial of […]

read more

Nivolumab and cabozantinib accepted for use within NHS Scotland for advanced kidney cancer

The Scottish Medicines Consortium (SMC), which reviews newly licensed medicines, has published advice recommending two new kidney cancer medicines for routine use by NHS Scotland. Nivolumab (Opdivo), an immunotherapy for advanced kidney cancer, was accepted following consideration through the SMC’s Patient and Clinician Engagement (PACE) process, which is for medicines used at the end of life […]

read more

Aflibercept shows promise in second-line treatment of advanced kidney cancer

A study reported in the online PracticeUpdate journal Renal Cell Carcinoma this week shows aflibercept, a vascular endothelial growth factor receptor (VEGFR) inhibitor, prolongs progression-free survival in people with previously treated advanced clear cell renal cell carcinoma (ccRCC). Patients with previously treated advanced or metastatic ccRCC were treated with one of two doses of aflibercept (1 […]

read more

Adjuvant therapy for high-risk localised kidney cancer

This literature review was published in The Journal of Urology recently, and reviews the progress made to date with adjuvant clinical trials in renal cell carcinoma (RCC). The review examined articles related to adjuvant therapy, including traditional immunotherapy (interleukin 2 and interferon), VEGF and mTOR inhibitors (targeted therapies), vaccines, and immune checkpoint inhibitors, for patients […]

read more

Immunotherapy combined with VEGF inhibitors for kidney cancer

In this video interview, Dr Shilpa Gupta, assistant professor, Haematology, Oncology and Transplantation Division, University of Minnesota, USA, discusses combining VEGF inhibitors with immunotherapy for patients with kidney cancer. Since kidney cancer is a VEGF-driven disease, it makes sense to combine VEGF inhibitors, such as sunitinib or axitinib, with immunotherapy drugs, such as nivolumab or […]

read more
Showing 61 to 67 of 67 results
  TOP